cbdMD (YCBD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jul, 2026Opening remarks and agenda
Meeting commenced virtually on March 30, 2026, with CEO/CFO Ronan Kennedy presiding and welcoming shareholders.
Attendees were informed about the agenda, conduct code, and procedures for submitting questions during the meeting.
Formal business was prioritized, with a plan to address additional questions after adjournment of the formal portion.
Board and executive committee updates
Directors and executive officers in attendance were introduced, including board members and the Chief Accounting Officer.
Brian Pearlman was appointed as Inspector of Elections for the meeting.
Corporate governance
Notice of meeting and proxy statement were distributed to shareholders of record as of February 2, 2026.
Proof of mailing and shareholder list procedures were confirmed and documented for transparency.
Quorum was established with over 33.3% of shares represented by proxy.
Latest events from cbdMD
- Operating loss narrowed, liquidity improved, and regulatory shifts may drive major growth in 2026.YCBD
Q4 20258 Jul 2026 - Revenue grew 19% to $5.6M, with Bluebird integration and Medicare channel shaping future growth.YCBD
Q2 202614 May 2026 - Resale registration for 2M shares highlights dilution risk and growth from Bluebird acquisition.YCBD
Registration Filing20 Feb 2026 - Q1 FY26 revenue rose 12% sequentially, with improved net loss and Bluebird acquisition boosting outlook.YCBD
Q1 202617 Feb 2026 - Eight key proposals, including a reverse split and major share issuances, up for virtual vote.YCBD
Proxy Filing12 Feb 2026 - Shareholders will vote on director elections, a reverse split, and major share issuances with dilution risk.YCBD
Proxy Filing2 Feb 2026 - Net sales fell 10.9%–12% as Oasis expanded, margins held, and regulatory headwinds persisted.YCBD
Q3 202523 Jan 2026 - Q2 FY25 saw higher sales, improved margins, and equity actions, but liquidity risks persist.YCBD
Q2 202523 Jan 2026 - Registering 2M shares for resale after $2.25M Series C raise, with focus on cost control and innovation.YCBD
Registration Filing22 Jan 2026